Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 1
1990 2
1991 1
1993 3
1994 2
1995 3
1996 8
1997 13
1998 15
1999 8
2000 18
2001 28
2002 55
2003 70
2004 76
2005 86
2006 115
2007 149
2008 154
2009 130
2010 136
2011 165
2012 203
2013 192
2014 198
2015 219
2016 206
2017 154
2018 147
2019 175
2020 219
2021 258
2022 263
2023 271
2024 306
2025 397
2026 414

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,238 results

Results by year

Filters applied: . Clear all
Page 1
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial.
Paterson DL, Sulaiman H, Liu PY, Chatfield MD, Yilmaz M, Salmuna ZN, Mazlan MZ, Anunnatsiri S, Sirijatuphat R, Chotiprasitsakul D, Lye DC, Somani J, Kalimuddin S, Aslan AT, Thamlikitkul V, Lee YT, Yang YS, Lin YT, Ramli WNW, Tseng CH, Archuleta S, Chan YFZ, Forde BM, Wright H, Stewart AG, Ramsay KA, Ling W, Rossi V, Harris-Brown TM, Harris PNA; GAME CHANGER Trial Investigators. Paterson DL, et al. Among authors: yilmaz m. Lancet Infect Dis. 2026 Feb;26(2):148-159. doi: 10.1016/S1473-3099(25)00469-4. Epub 2025 Oct 6. Lancet Infect Dis. 2026. PMID: 41067237 Clinical Trial.
Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy.
Savarese G, Lindberg F, Cannata A, Adamo M, Ambrosio G, Ameri P, Anker MS, Bäck M, Bayes-Genis A, Ben Gal T, Braunschweig F, Chioncel O, D'Elia E, El-Tamimi H, Filippatos G, Girerd N, Hill L, Jankowska E, Khunti K, Lewis BS, Moura B, Amir O, Paolillo S, Piepoli M, Shehab A, Simpson M, Skouri H, Stolfo D, Tocchetti CG, Vitale C, Volterrani M, von Haehling S, Wassmann S, Yilmaz MB, Kaski JC, Dobrev D, Metra M, Rosano GMC. Savarese G, et al. Among authors: yilmaz mb. Eur J Heart Fail. 2025 Dec;27(12):2716-2731. doi: 10.1002/ejhf.70090. Epub 2025 Nov 9. Eur J Heart Fail. 2025. PMID: 41208145 Free PMC article. Review.
2025 ICM: Spacers.
Fink B, Yılmaz MK, Yazdi H, Veltman ES, De Meo D, Castan A, Squire M, Rodriguez D, Adravanti P, Azboy İ, Babiak I, Bedard NA, Benevenia J, Burgo FJ, Cabrita HB, Cacciola G, Dave D, De Meo F, Falotico GG, George C, Ghadi I, Girgulsky GB, Haghbin M, Hassaballa M, Hilton T, Mađjarević T, Moojen DJF, Olufemi T, Russo A, Sambri A, Sauer J, Sayol RR, Sharma RK, Stambough JB, Stelwagen MH, Suárez R, Tarity TD, Tetsworth KD, Tian H, Tsai SW, Tsuchiya H, Wolfstadt J. Fink B, et al. Among authors: yilmaz mk. J Arthroplasty. 2025 Dec;41(1S1):S341-S361. doi: 10.1016/j.arth.2025.10.106. Epub 2025 Oct 30. J Arthroplasty. 2025. PMID: 41176105 No abstract available.
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias.
Senapati J, Konopleva M, Issa GC, Jabbour E, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Short NJ, Yilmaz M, Deshmukh I, Alvarez J, Loghavi S, Tang G, Abbas HA, Andreeff M, Bhalla K, Midde NM, Said N, Noyalis A, Mires DE, Ning J, Xiao L, Ravandi F, Garcia-Manero G, Kantarjian HM, Daver NG. Senapati J, et al. Among authors: yilmaz m. J Hematol Oncol. 2025 Nov 27;18(1):108. doi: 10.1186/s13045-025-01757-4. J Hematol Oncol. 2025. PMID: 41310838 Free PMC article. Clinical Trial.
Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.
Short NJ, Kantarjian H, Daver N, Azevedo RS, Karrar O, DiNardo CD, Kadia T, Yilmaz M, Maroun M, Hachem M, Borthakur G, Issa GC, Shpall EJ, Popat U, Huang X, Qiao W, Nasr L, Macaron W, Abramova R, Garcia-Manero G, Konopleva M, Ravandi F. Short NJ, et al. Among authors: yilmaz m. Blood Adv. 2026 Sep 8;10(17):5743-5750. doi: 10.1182/bloodadvances.2026019841. Blood Adv. 2026. PMID: 42200455 Free PMC article. Clinical Trial.
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.
Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N. Short NJ, et al. Among authors: yilmaz m. Haematologica. 2026 Apr 1;111(4):1246-1253. doi: 10.3324/haematol.2025.288553. Epub 2025 Oct 2. Haematologica. 2026. PMID: 41035402 Free PMC article.
Sodium-glucose cotransporter 2 inhibitors and atherosclerosis.
Ceasovschih A, Balta A, Aldeen ES, Bianconi V, Barkas F, Şener YZ, Jakubová M, Yilmaz MB, Banach M, Șorodoc L, Șorodoc V. Ceasovschih A, et al. Among authors: yilmaz mb. Am J Prev Cardiol. 2025 Jul 18;23:101061. doi: 10.1016/j.ajpc.2025.101061. eCollection 2025 Sep. Am J Prev Cardiol. 2025. PMID: 40777543 Free PMC article. Review.
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.
Kadia TM, Bataller A, Bazinet A, Borthakur G, Daver N, Short NJ, DiNardo C, Jabbour E, Rausch CR, Issa GC, Pemmaraju N, Ohanian M, Maiti A, Montalban-Bravo G, Sasaki K, Bouligny IM, Yilmaz M, Haddad FG, Masarova L, Chien K, Alvarado Y, Jain N, Popat U, Shpall E, Loghavi S, Qiao W, Wang X, Garcia-Manero G, Ravandi F, Kantarjian HM. Kadia TM, et al. Among authors: yilmaz m. Am J Hematol. 2026 Jul;101(7):1737-1747. doi: 10.1002/ajh.70328. Epub 2026 Apr 25. Am J Hematol. 2026. PMID: 42035228 Clinical Trial.
4,238 results